137 related articles for article (PubMed ID: 2454893)
1. Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.
Cryz SJ; Sadoff JC; Fürer E
Infect Immun; 1988 Jul; 56(7):1829-30. PubMed ID: 2454893
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Sadoff JC; Ohman D; Fürer E
J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Furer E; Sadoff JC; Germanier R
Infect Immun; 1986 Apr; 52(1):161-5. PubMed ID: 3082756
[TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
Cryz SJ; Sadoff JC; Fürer E; Germanier R
J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans.
Cryz SJ; Cross AS; Sadoff JC; Wegmann A; Que JU; Fürer E
J Infect Dis; 1991 May; 163(5):1040-5. PubMed ID: 1708398
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously.
Edelman R; Taylor DN; Wasserman SS; McClain JB; Cross AS; Sadoff JC; Que JU; Cryz SJ
Vaccine; 1994 Nov; 12(14):1288-94. PubMed ID: 7856293
[TBL] [Abstract][Full Text] [Related]
8. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
[TBL] [Abstract][Full Text] [Related]
9. Clearance of Pseudomonas aeruginosa from normal rat lungs after immunization with somatic antigens or toxin A.
Johansen HK; Cryz SJ; Høiby N
APMIS; 1994 Jul; 102(7):545-53. PubMed ID: 7917224
[TBL] [Abstract][Full Text] [Related]
10. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Sadoff JC; Fürer E
Microb Pathog; 1989 Jan; 6(1):75-80. PubMed ID: 2733597
[TBL] [Abstract][Full Text] [Related]
11. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice.
Holder IA; Neely AN; Frank DW
Infect Immun; 2001 Sep; 69(9):5908-10. PubMed ID: 11500471
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.
Cryz SJ; Sadoff JC; Cross AS; Fürer E
Antibiot Chemother (1971); 1989; 42():177-83. PubMed ID: 2512836
[No Abstract] [Full Text] [Related]
13. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.
Bruderer U; Cryz SJ; Schaad UB; Deusinger M; Que JU; Lang AB
J Infect Dis; 1992 Aug; 166(2):344-9. PubMed ID: 1634805
[TBL] [Abstract][Full Text] [Related]
14. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Lang AB; Schaad UB; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Cryz SJ
J Pediatr; 1995 Nov; 127(5):711-7. PubMed ID: 7472821
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
Pier GB
J Clin Invest; 1982 Feb; 69(2):303-8. PubMed ID: 6799548
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
Shinefield HR; Black S; Ray P; Chang I; Lewis N; Fireman B; Hackell J; Paradiso PR; Siber G; Kohberger R; Madore DV; Malinowski FJ; Kimura A; Le C; Landaw I; Aguilar J; Hansen J
Pediatr Infect Dis J; 1999 Sep; 18(9):757-63. PubMed ID: 10493334
[TBL] [Abstract][Full Text] [Related]
17. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.
MacDonald NE; Halperin SA; Law BJ; Forrest B; Danzig LE; Granoff DM
JAMA; 1998 Nov; 280(19):1685-9. PubMed ID: 9832000
[TBL] [Abstract][Full Text] [Related]
18. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.
Cryz SJ; Lang AB; Sadoff JC; Germanier R; Fürer E
Infect Immun; 1987 Jul; 55(7):1547-51. PubMed ID: 3110065
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis.
Schaad UB; Lang AB; Wedgwood J; Ruedeberg A; Que JU; Fürer E; Cryz SJ
Lancet; 1991 Nov; 338(8777):1236-7. PubMed ID: 1682645
[TBL] [Abstract][Full Text] [Related]
20. A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Sadoff JC; Germanier R
Antibiot Chemother (1971); 1987; 39():249-55. PubMed ID: 3118786
[No Abstract] [Full Text] [Related]
[Next] [New Search]
